According to a new report Asia Pacific Meningococcal Vaccine Market, published by KBV research, the Asia Pacific Meningococcal Vaccine Market would witness market growth of 9.9% CAGR during the forecast period (2020-2026).
The China market dominated the Asia Pacific Infants (0 to 2 years) Market by Country in 2019, and would continue to be a dominant market till 2026. The India market is anticipated to witness a CAGR of 12.8% during (2020 - 2026). Additionally, The Japan market is exhibiting a CAGR of 12.9% during (2020 - 2026).
The Bexsero market dominated the South Korea Meningococcal Vaccine Market by Brand in 2019, growing at a CAGR of 10.7 % during the forecast period. The Trumenba market is estimated to grow at a CAGR of 11% during (2020 - 2026).
The Quadrivalent market dominated the Malaysia Meningococcal Vaccine Market by Type in 2019, thereby, achieving a market value of $23.1 Million by 2026. The Bivalent market would showcase a CAGR of 11.7% during (2020 - 2026).
Full Report: https://www.kbvresearch.com/asia-pacific-meningococcal-vaccine-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of GlaxoSmithKline PLC (GSK), Pfizer, Inc., Sanofi S.A., Walvax Biotechnology Co., Ltd., Bio-Manguinhos (Oswaldo Cruz Foundation), Bio-Med Pvt. Ltd., Chongqing Zhifei Biological Products Co., Ltd., Hualan Biological Engineering, Inc., Incepta Pharmaceuticals Ltd. and Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)
By Brand
By Type
By Age Group
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
